Physicians' Academy for Cardiovascular Education

Atrial fibrillation

Rigorous assessment of effect of individual triggers for AF

3' education - Nov. 15, 2021 - Prof. Gregory Marcus, MD

Screening for AF with irregular heart rhythm detection by Fitbit wearables

3' education - Nov. 14, 2021 - Steven Lubitz, MD

NOAC as possible treatment option in patients with AF after successful TAVI

5' education - Sep. 13, 2021 - Prof. Nicolas van Mieghem, MD, PhD

Head-to-head comparison of risk scores for ischemic stroke in patients with AF and CKD

5' education - June 14, 2001 - Ype de Jong, MD

Updates in the 2020 AF guidelines

3' education - Sep. 2, 2020 - Prof. Isabelle van Gelder, MD

Early rhythm control in AF patients improves outcomes

3' education - Aug. 29, 2020 - Prof. Paulus Kirchhof, MD

Oral anticoagulant monotherapy reduces bleeding in AF patients after TAVI

3' education - Mar. 30, 2020 - Dr. Jur ten Berg, MD, PhD - ACC 2020

Challenges in prescribing DOACs for stroke prevention in AF

5' education - Mar. 2, 2020 - Prof. Freek Verheugt and John Eikelboom

Smartphone-based AF screening in the general population

5' education - Oct. 28, 2019 - Paris, France - Tine Proesmans

Clear results with NOAC monotherapy in patients with CAD and AF

3' education - Sep. 2, 2019 - Prof. Freek Verheugt

Better outcomes in patients with AF and ACS/PCI with NOAC vs. VKA and when dropping aspirin

3' education - Mar. 17, 2019 - New Orleans, LA, USA - John Alexander, MD

Proof-of-concept study shows 84% true AF in those with irregular pulse detected with smartwatch

3' education - Mar. 16, 2019 - New Orleans, LA, USA - Michael Valentine, MD

Population screening for atrial fibrillation with a smartphone

10' education - Aug. 26, 2018 - Munich, Germany - Prof. dr. Pieter Vandervoort - Genk, Belgium

Atrial fibrillation & HFpEF: Novel device and therapeutic approaches

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Dipak Kotecha - Birmingham, UK - Online CME

Considerations on antithrombotic treatment of VTE and AF patients

10' education - Mar. 8, 2018 - Prof. Menno Huisman and dr. Alexander Cohen

Neurotoxin injection did not prevent the common complication of AF after cardiac surgery

3' education - Nov. 15, 2017 - AHA 2017 - Anaheim, CA, USA - Nathan Waldron, MD - Durham, NC, USA.

Initiating digoxin in AF patients associated with early hazard of sudden death

3' education - Mar. 19, 2017 - ACC 2017, Washington, DC, USA - Dr. Renato Lopes

Tailoring oral anticoagulation in elderly patients with AF

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Christopher B. Granger, MD (Durham, NC, USA)

Outstanding questions and ongoing studies on the use of NOACs

3' education - Oct. 7, 2016 - Berg en Dal, The Netherlands - Prof. Chris Granger, MD (Durham, NC, USA)

Oral anticoagulation in daily clinical practice in varous patient populations

10' education - Oct. 6, 2016 - The Netherlands - Prof. Chris Granger, MD (Durham, NC, USA) and Marc Brouwer, MD (Nijmegen, The Netherlands)

Inadequate anticoagulant treatment for stroke prevention in atrial fibrillation

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Christian T. Ruff, MD - Boston, MA, USA
##SCROLLER_ITEMS_FULL_TITLE##

Where are we with HF patients with AF?

3' education - Oct. 31, 2015 - HF Summit, Barcelona, Spain - Dr. Dipak Kotecha
##SCROLLER_ITEMS_FULL_TITLE##

Translating new clinical trial data of DOACs for stroke prevention into clinical practice

3' education - Mar. 30, 2014 - VBWG at ACC - Michael Ezekowitz MD, PhD

Anticoagulation reversal in patients with acute bleeding during oral factor Xa inhibitor therapy

Literature - Jan. 17, 2022 - Benz AP et al. - Thromb Haemost. 2022

Andexanet alfa specifically binds and sequesters factor Xa inhibitors. A study investigated the efficacy and safety of andexanet alfa in patients on edoxaban with acute major bleeding.

Rigorous assessment of effect of individual triggers for AF

3' education - Nov. 15, 2021 - Prof. Gregory Marcus, MD
In this video, prof. Marcus explains the methodology of n-of-1 trials in the I-STOP-AF trial and summarizes the findings.

AHA 2021 In this video, prof. Marcus explains the methodology of n-of-1 trials in the I-STOP-AF trial and summarizes the findings.

Testing individual triggers for AF in n-of-1 trials

News - Nov. 15, 2021

AHA 2021 In the I-STOP AF trial, n-of-1 trials with individual triggers did not result in a change in AF-related quality of life compared to monitoring only.

Screening for AF with irregular heart rhythm detection by Fitbit wearables

3' education - Nov. 14, 2021 - Steven Lubitz, MD
The Fitbit Heart study examined whether a novel photoplethysmography (PPG) software algorithm for Fitbit wearables can identify atrial fibrillation in a large population.

AHA 2021 The Fitbit Heart study examined whether a novel photoplethysmography (PPG) software algorithm for Fitbit wearables can identify atrial fibrillation in a large population.

Novel algorithm using irregular heart rhythm detection by Fitbit wearables for AF screening

News - Nov. 14, 2021
A novel software algorithm with input of irregular heart rhythm detection by Fitbit wearables had a positive predictive value of 98% for undiagnosed atrial fibrillation (AF).

AHA 2021 A novel software algorithm with input of irregular heart rhythm detection by Fitbit wearables had a positive predictive value of 98% for undiagnosed atrial fibrillation (AF).

No difference in cognitive outcomes in AF patients on DOAC vs. warfarin

News - Nov. 14, 2021

AHA 2021 The majority of cognitive outcome tests was not different between AF patients treated with dabigatran or warfarin after two years in the GIRAF trial.

Association of DOACs with adverse outcomes in older patients with AF across frailty subgroups

Literature - Oct. 19, 2021 - Kim DH, et al. - Annals of Internal Medicine 2021

Using data of Medicare claims, this study investigated whether frailty affected the effect of dabigatran, rivaroxaban, or apixaban vs. warfarin on adverse outcomes in AF patients ≥65 years.

Under- and overdosing of DOACs still common in patients with AF

Literature - Sep. 27, 2021 - Moudallel S et al. - Br J Clin Pharmacol. 2021

This study found inappropriate DOAC prescriptions in 16.9% of hospitalized patients with AF, with underdosing being more common than overdosing. Moreover, this study identified determinants of DOAC under- and overdosing.

NOAC as possible treatment option in patients with AF after successful TAVI

5' education - Sep. 13, 2021 - Prof. Nicolas van Mieghem, MD, PhD
In the ENVISAGE-TAVI AF trial, the effect of edoxaban on net adverse clinical events (NACE)  was compared to VKAs in elderly patients with AF who underwent TAVI.

ESC 2021 In the ENVISAGE-TAVI AF trial, the effect of edoxaban on net adverse clinical events (NACE) was compared to VKAs in elderly patients with AF who underwent TAVI.

Continuous monitoring for unknown AF and OAC if indicated does not prevent stroke

News - Aug. 29, 2021

ESC 2021 The LOOP study showed that continuous heart rhythm monitoring using an implantable loop recorder and initiation of OAC if AF was detected, did not prevent stroke in patients at high risk compared to standard care.

NOAC non-inferior to VKA for net adverse clinical events in AF patients after TAVI

News - Aug. 28, 2021

ESC 2021 Non-inferiority was met for edoxaban when compared with VKA for net adverse clinical events (NACE) in patients with AF after TAVI, but major bleeding was higher in those receiving edoxaban.

Clinical effects sGC stimulator in HFrEF after a worsening HF event unaffected by AF status

News - July 5, 2021

ESC HF 2021 This analysis of the VICTORIA trial showed that the beneficial effects of vericiguat were unaffected by AF status at baseline.